Artara Therapeutics Inc (TARA) Stock Price, Quote & News

Company Profile

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving pare...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 844 0337

Website: www.protaratx.com

Address:

345 Park Avenue South, 3rd Floor, New York, United States

lovestockstwits Jan. 16 at 10:31 PM

$TARA IBRX is way ahead and will file for NDA soon

1 · Reply

Rolo2024 Jan. 16 at 7:01 PM

$TARA Theres enough cash on hand for 3 years and revenues potentially will not start until 4 years. Let's trust our data that we will receive breakout news in 1-2 years that will propel this stock into double digits $10-$12 by end of the year. Sporting around a $3 average so this will be better that putting into a dividend stock for now.

0 · Reply

longterminvs Jan. 15 at 9:29 PM

$TARA I bought more today. I've been holding off since my original position was $2.33. I have a hard time paying more, my mental problem. I was listening to Biotech TV, interview with Perceptive Advisors CEO where he said "sometimes you get more information about a company and you buy more at a higher price." I bought more. Some good reviews at JPM, as pablo4 pointed out, but CEO set some very aggressive benchmarks for data and if they hit that it's a best in class drug. Lets hope the data reflects his confidence.

0 · Reply

lovestockstwits Jan. 15 at 1:15 PM

$TARA running

0 · Reply

pablo4 Jan. 15 at 12:07 AM

$TARA CEO said a likely approval in 2027, one in 2028, one in 2029, and one in 2030

0 · Reply

pablo4 Jan. 15 at 12:04 AM

$TARA Whoever has been selling TARA is going to regret it very soon, IMO. This company has it going and the CEO is excellent! JMO

0 · Reply

pablo4 Jan. 14 at 11:53 PM

$TARA CEO just defended an expectation of successful results in the TARA 002 Unresponsive group coming in February.

0 · Reply

pablo4 Jan. 14 at 11:50 PM

$TARA CEOjust affirmed bladder cancer results come in February.

1 · Reply

pablo4 Jan. 14 at 7:30 PM

$TARA there could be some interesting stuff in the presentation today at JP Morgan....rally time?

0 · Reply

pablo4 Jan. 14 at 7:19 PM

$TARA presentation today at 4:45 ET and 5:45 CT

2 · Reply

Protara Therapeutics, Inc. (TARA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:00 AM EST - 4 days ago

Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

Jan 7, 2026, 8:00 AM EST - 9 days ago

Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:00 AM EST - 11 days ago

Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations

Dec 8, 2025, 4:05 PM EST - 5 weeks ago

Protara Announces Closing of $75 Million Public Offering

Dec 4, 2025, 10:03 PM EST - 6 weeks ago

Protara Announces Pricing of $75 Million Public Offering

Dec 4, 2025, 4:15 PM EST - 6 weeks ago

Protara Announces Proposed Public Offering

Dec 4, 2025, 7:30 AM EST - 6 weeks ago

Protara Therapeutics: End Of 2025 Proving Eventful Indeed

Dec 3, 2025, 3:43 PM EST - 6 weeks ago

Protara Therapeutics, Inc. (TARA) Discusses Updated Interim Results for TARA-002 in Phase II ADVANCE-2 Trial for BCG-Naive NMIBC Patients Transcript

Dec 3, 2025, 8:00 AM EST - 6 weeks ago

Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients

Dec 1, 2025, 4:15 PM EST - 6 weeks ago

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025

Nov 19, 2025, 2:53 PM EST - 2 months ago

Protara Therapeutics, Inc. (TARA) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations Transcript

Nov 19, 2025, 8:00 AM EST - 2 months ago

Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Nov 18, 2025, 4:30 PM EST - 2 months ago

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025

Nov 17, 2025, 8:00 AM EST - 2 months ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology

Nov 10, 2025, 8:00 AM EST - 2 months ago

Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 4:05 PM EST - 2 months ago

Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace

Oct 1, 2025, 4:03 PM EDT - 3 months ago

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 27, 2025, 8:00 AM EDT - 5 months ago

Protara Therapeutics to Participate in Upcoming Investor Conferences

Aug 11, 2025, 8:00 AM EDT - 5 months ago

Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Jun 30, 2025, 8:00 AM EDT - 7 months ago

Protara Therapeutics Announces Addition to the Russell 3000® Index

Jun 2, 2025, 4:04 PM EDT - 8 months ago

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

May 8, 2025, 8:00 AM EDT - 9 months ago

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Apr 26, 2025, 10:00 AM EDT - 9 months ago

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Apr 23, 2025, 8:00 AM EDT - 9 months ago

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

Apr 15, 2025, 4:13 PM EDT - 9 months ago

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

Apr 10, 2025, 4:05 PM EDT - 10 months ago

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

Mar 28, 2025, 5:10 PM EDT - 10 months ago

Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results

Mar 19, 2025, 8:00 AM EDT - 10 months ago

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Mar 5, 2025, 8:00 AM EST - 11 months ago

Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Feb 26, 2025, 8:00 AM EST - 11 months ago

Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Jan 13, 2025, 8:00 AM EST - 1 year ago

Protara Highlights Recent Updates and Anticipated 2025 Milestones

Dec 14, 2024, 8:30 AM EST - 1 year ago

Protara Therapeutics: Rising From The Ashes

Dec 11, 2024, 4:05 PM EST - 1 year ago

Protara Announces Closing of $100 Million Public Offering

Dec 10, 2024, 5:00 PM EST - 1 year ago

Protara Therapeutics: Carving New Roads In Bladder Cancer

Dec 10, 2024, 3:55 PM EST - 1 year ago

Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst

Dec 9, 2024, 11:35 PM EST - 1 year ago

Protara Announces Pricing of $100 Million Public Offering

Dec 5, 2024, 10:50 AM EST - 1 year ago

Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?

Nov 15, 2024, 5:52 PM EST - 1 year ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Nov 6, 2024, 8:00 AM EST - 1 year ago

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Oct 21, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Sep 9, 2024, 8:05 AM EDT - 1 year ago

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Jun 24, 2024, 5:06 PM EDT - 1 year ago

Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 21, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit

May 2, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update

Apr 5, 2024, 8:04 AM EDT - 1 year ago

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

Apr 5, 2024, 8:02 AM EDT - 1 year ago

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Apr 5, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

lovestockstwits Jan. 16 at 10:31 PM

$TARA IBRX is way ahead and will file for NDA soon

1 · Reply

Rolo2024 Jan. 16 at 7:01 PM

0 · Reply

longterminvs Jan. 15 at 9:29 PM

0 · Reply

lovestockstwits Jan. 15 at 1:15 PM

$TARA running

0 · Reply

pablo4 Jan. 15 at 12:07 AM

$TARA CEO said a likely approval in 2027, one in 2028, one in 2029, and one in 2030

0 · Reply

pablo4 Jan. 15 at 12:04 AM

$TARA Whoever has been selling TARA is going to regret it very soon, IMO. This company has it going and the CEO is excellent! JMO

0 · Reply

pablo4 Jan. 14 at 11:53 PM

$TARA CEO just defended an expectation of successful results in the TARA 002 Unresponsive group coming in February.

0 · Reply

pablo4 Jan. 14 at 11:50 PM

$TARA CEOjust affirmed bladder cancer results come in February.

1 · Reply

pablo4 Jan. 14 at 7:30 PM

$TARA there could be some interesting stuff in the presentation today at JP Morgan....rally time?

0 · Reply

pablo4 Jan. 14 at 7:19 PM

$TARA presentation today at 4:45 ET and 5:45 CT

2 · Reply

pablo4 Jan. 13 at 9:55 PM

$TARA P.S. If what I wrote just below is true, how stupid can selling be? And what a buying opportunity was today!!! Results are still coming this quarter and the stock has been firing on all cylinders. JMO

1 · Reply

pablo4 Jan. 13 at 9:53 PM

$TARA After considering everything, it's pretty obvious what's happening, IMO. TARA announced premarket on Wed., Jan. 7, that it would be presenting at JP Morgan tomorrow, the 14th. TARA had closed at 5.12/share on the 6th. It gapped up on the news Wednesday on over 1.2M shares to reach 5.87 & close at 5.69. It closed at 5.75 on Friday, the 9th. Investors wondered if bladder cancer news expected this quarter w/be presented at JP Morgan, IMO. But yesterday, the 12th, news came out premarket and provided a corporate update. I believe the following quote brought in the selling: "in BCG-Naïve NMIBC patients, we look forward to providing an interim update on the registrational BCG-Unresponsive trial later this quarter.” The sentence says a lot..."we look forward"...that should ease concerns of any bad news at JP Morgan tomorrow. But, "later this quarter" tells the market no results tomorrow...thus it ran up last week on expecting news tomorrow and has fallen now that it's not expected. JMO

0 · Reply

thenumbersdontlie Jan. 13 at 9:22 PM

$TARA bs news release, manipulating volume, bring the action

0 · Reply

elmono Jan. 13 at 6:39 PM

$TARA I’ll be honest: bought a lot more, increased position by 50%

1 · Reply

pablo4 Jan. 13 at 6:27 PM

$TARA one last post. I calculated cash per share as of right now of 3.75 to 3.80 based on the additional shares and money from the recent capital raise at 5.75/share. As of this moment, TARA has a runway (per the company) well into 2028. It has shown glowing statistical results for TARA 002 in bladder cancer, in LM formations, and choline chloride for PS patients....thus for its entire pipeline. It has major upcoming catalysts this year. Analysts' consensus 12 month target is 24.83 and very doable, IMO. There are 6 major analysts weighing in at tipranks and they are clustered from a low target of 21 to a high target of 30. Yea, why wouldn't I be adding like crazy here? JMO

1 · Reply

pablo4 Jan. 13 at 6:17 PM

$TARA how long this seller lasts, I don't know....but it's a steal, IMO. I added a ton of trading shares today to my large core position. I've been trying to exit the market.....and then I get sucked in by deals.....I've got to learn to close my eyes to it:)

1 · Reply

pablo4 Jan. 13 at 5:52 PM

$TARA in light of that glowing update on TARA we just got on all its pipeline prospects looking ahead in this year, what a remarkable opportunity to gain shares now, IMO. I took full advantage today. JMO

0 · Reply

barkNdunbite Jan. 12 at 6:54 PM

$TARA Noted: NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy and Fast Track designations for TARA-002

0 · Reply

lowrisku Jan. 12 at 6:10 PM

$TARA Illiquid tape, if it bases tight and volume expands you can see outsized candles fast

0 · Reply

Eagley3k Jan. 12 at 5:52 PM

$TARA was the PR today that bad 🤪

0 · Reply

elmono Jan. 12 at 3:54 PM

$TARA algo’s taking it down…,call me a buyer

0 · Reply

DARKP00L Jan. 12 at 12:36 PM

$TARA 07:17 on Jan. 12 2026 Protara Therapeutics Enters 2026 With Advancing TARA-002 Programs, Registrational Trials And Extended Cash Runway Into 2028 #tradeideas

0 · Reply

Market Cap	260.22M
Revenue (ttm)	0.00
Net Income (ttm)	-44.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,172,300
Avg Vol	984,588
Day's Range	N/A - N/A
Shares Out	51.63M
Stochastic %K	23%
Beta	1.42
Analysts	Strong Sell
Price Target	$24.83